Loading…
Lobbying Spend
—
Filings
43
Firms Hired
1
Active Period
2013–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Veterans Pain Management Improvement Act
2017 · third_quarter · Firm: FOLEY HOAG LLP
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Implementation of 21st Century Cures Act.
Client expense: — · Firm income: $30,000
Matched citations: HR 1628
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Implementation of 21st Century Cures Act.
Client expense: — · Firm income: $30,000
Matched citations: HR 2430
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Implementation of 21st Century Cures Act.
Client expense: — · Firm income: $30,000
Matched citations: S. 1878
Historic Downtown Preservation and Access Act
2017 · third_quarter · Firm: FOLEY HOAG LLP
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Implementation of 21st Century Cures Act.
Client expense: — · Firm income: $30,000
Matched citations: S.932
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
Client expense: — · Firm income: $30,000
Matched citations: HR 1628
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
Client expense: — · Firm income: $30,000
Matched citations: HR 2430
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
Client expense: — · Firm income: $30,000
Matched citations: S. 1878
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
Client expense: — · Firm income: $30,000
Matched citations: S.932
-Implementation of Orphan Drug Act and orphan drug development. -21st Century Cures Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -ACA Implementation -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
Client expense: — · Firm income: $30,000
Matched citations: S. 1878
Implementation of Orphan Drug Act and orphan drug development. H.R. 6 - 21st Century Cures Act. Senate legislation on biomedical innovation. S. 1878 "Advancing Hope Act of 2016" Pending healthcare legislation and potential impact on the biopharmaceutical industry Affordable Care Act implementation Re-authorization of Prescription Drug User Fee Act (PDUFA) Re-authorization of the pediatric rare disease priority review voucher
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
Implementation of Orphan Drug Act and orphan drug development. H.R. 6 - 21st Century Cures Act. Senate legislation on biomedical innovation. S. 1878 "Advancing Hope Act of 2016" Pending healthcare legislation and potential impact on the biopharmaceutical industry Affordable Care Act implementation Re-authorization of Prescription Drug User Fee Act (PDUFA) Re-authorization of the pediatric rare disease priority review voucher
Client expense: — · Firm income: $30,000
Matched citations: S. 1878
Implementation of Orphan Drug Act and orphan drug development. H.R. 6, 21st Century Cures Act. Senate legislation on biomedical innovation. Pending healthcare legislation and potential impact on the biopharmaceutical industry Affordable Care Act implementation Reauthorization of Prescription Drug User Fee Act (PDUFA)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
Implementation of Orphan Drug Act and orphan drug development. H.R. 6, 21st Century Cures Act. Senate legislation on biomedical innovation.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 6
Source: Senate LDA